Search results
Results from the WOW.Com Content Network
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
Price Action: MRK stock is down 0.79% at $90.02 at the last check on Wednesday. Read Next: T-Mobile Raises $2.94 Billion To Fund Stock Buybacks, Dividends, and Debt Refinancing.
Merck is forecasting 2024 revenue to climb by 5% to 7% over the 2023 result, while its earnings-per-share (EPS) target of $7.94 to $8.04 represent a midpoint increase of 7% from the company record ...
This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
Merck (MRK) closed at $86.95 in the latest trading session, marking a +0.78% move from the prior day.
Merck (MRK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.